Once we complete the OPTIMIZE study, we’re moving on to the next series of studies we call ACCELERATE. And so this is carrying on the theme of trying to improve outcomes in recipients of mismatched unrelated donor transplant. But for the first time, we’re actually now entering the realm of randomized trials. And so the ACCELERATE study is what we call a platform study, which will be randomizing the standard of care that we used on ACCESS, which is the standard doses of PTCy...
Once we complete the OPTIMIZE study, we’re moving on to the next series of studies we call ACCELERATE. And so this is carrying on the theme of trying to improve outcomes in recipients of mismatched unrelated donor transplant. But for the first time, we’re actually now entering the realm of randomized trials. And so the ACCELERATE study is what we call a platform study, which will be randomizing the standard of care that we used on ACCESS, which is the standard doses of PTCy. And we’re going to look at combinations of lower dose PTCy with other agents like ruxolitinib and abatacept in a randomized fashion once we prove that those combinations are safe. So we think we’re really going to learn how these interventions may change outcomes in these patients. And so we’re very excited about the next series of studies on the ACCELERATE platform.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
